GHRH (Growth Hormone-Releasing Hormone)

GHRH is the hypothalamic hormone that tells your pituitary to release growth hormone. It's a 44-amino-acid peptide produced in the hypothalamus, released in pulses, and carried to the pituitary through the portal blood supply. Several research peptides are synthetic analogs of GHRH — meaning they bind the same receptor and produce the same downstream effect (GH release) without being the natural hormone itself. Sermorelin is a synthetic fragment of the first 29 amino acids of GHRH — the biologically active portion. CJC-1295 is a modified version with a Drug Affinity Complex (DAC) that extends its half-life from minutes to days by binding plasma albumin. Tesamorelin is a stabilised full-length analog and is the only one with FDA drug approval, for a specific indication. All GHRH analogs share one limitation: they work by stimulating a pituitary that can still respond. If pituitary function is significantly impaired, the response will be reduced proportionally. This is why baseline IGF-1 measurement before and during use is standard in the clinical literature on GHRH-analog research.